Xtl Biopharmaceuticals Ltd (XTLB) SEC Filings — 2025
12 SEC filings for Xtl Biopharmaceuticals Ltd (XTLB) in 2025.
Filings
- XTL Biopharma Reports H1 2025 Results Amid Shareholder Dispute — 6-K · Dec 30, 2025
- XTL Biopharma Faces Nasdaq Minimum Bid Price Deficiency — 6-K · Dec 29, 2025
- XTL Biopharma Subsidiary Sees CEO & CTO Resign — 6-K · Dec 12, 2025
- XTL Biopharma CFO Resigns, New CFO Appointed — 6-K · Dec 5, 2025
- XTL Biopharmaceuticals Board Changes — 6-K · Oct 23, 2025
- XTL Biopharma Holds Shareholder Meeting — 6-K · Jul 28, 2025
- XTL Biopharm Postpones Shareholder Meeting Due to Lack of Quorum — 6-K · Jul 21, 2025
- XTL Biopharma Sets Shareholder Meeting for July 21 — 6-K · Jun 13, 2025
- XTL Biopharmaceuticals Files 2024 Annual Report — 20-F · Apr 30, 2025
- XTL Biopharmaceuticals Appoints New CEO, Noam Band — 6-K · Apr 7, 2025
- XTL Biopharma Grants Exclusive Sublicense to Biossil Inc. — 6-K · Mar 4, 2025
- XTL Biopharma Settles with Social Proxy CEO, Shareholder Director Rights — 6-K · Feb 3, 2025